← board
LXRX
Lexicon Pharmaceuticalsdistress 4/10 · elevated risk$2.26+0%today-14% from 52w high
Lead: hypertrophic cardiomyopathy
Revenue
$21M
Liquidity
$171M
Runway
4.4 yrs
Shares 1y
+22%
Price & events
+28.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
+0.9%
1W
+4.6%
1M
+34.5%
3M
+32.9%
6M
+86.8%
1Y
+1.8%
2Y
-33.5%
5Y
-35.8%
All
Overview
- Market Cap
- $1.00B
- Enterprise Value
- $1.02B
- Volume
- 175.26K
- 52 Week Range
- $1.02 – $2.64
- Total Shares
- 444.20M
- Float Shares
- 262.53M
- Short %
- 13.08%
- % Held by Insiders
- 1.12%
- % Held by Institutions
- 78.52%
- RVOL
- 0.04x
- Beta
- 1.05
Pipeline stages · 1 programs
Sotagliflozin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-01 | Phase 3 | Sotagliflozin | Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | — | recruiting |
Catalyst news & presentations · 4
- first quarter of 2027Guided 70%readoutPhase 3sotagliflozin · Topline results from SONATA-HCM Phase 3 studySEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)sotagliflozin · Potential NDA resubmission for ZYNQUISTA in T1D based on STENO1 dataSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026enrollment completesecondaryPhase 3sotagliflozin · Enrollment completion for SONATA-HCM pivotal Phase 3 study targeting 500 patientsSEC 8-K
Approved drugs (1)
- INPEFASOTAGLIFLOZIN2023 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $4 (+67% upside) · 5 analysts
- 2026-05-11CitigroupBuy
- 2026-03-23HC Wainwright & Co.Buy
- 2026-03-10CitigroupBuy
- 2026-03-05HC Wainwright & Co.Buy
- 2025-09-02HC Wainwright & Co.Buy
- 2025-08-07CitigroupBuy
Competitors — hypertrophic cardiomyopathy
Recent news
- 2026-07-10What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders - simplywall.st
- 2026-07-03Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion - Yahoo Finance
- 2026-07-01How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX) - simplywall.st
- 2026-06-30Lexicon Pharmaceuticals (LXRX) Joins Russell Indexes, Is The Stock Still A Bargain? - simplywall.st
- 2026-06-29Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
- 2026-06-29Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 2000 Index - marketscreener.com
- 2026-06-29Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark - marketscreener.com
- 2026-06-29Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.